Ryan Savitz's most recent trade in Dianthus Therapeutics Inc was a trade of 31,249 Common Stock done at an average price of $21.8 . Disclosure was reported to the exchange on July 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 09 Jul 2026 | 31,249 | 31,249 | - | 21.8 | 680,291 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2026 | 31,249 | 68,751 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 101.24 per share. | 09 Jul 2026 | 15,329 | 5,566 | - | 101.2 | 1,551,908 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 100.22 per share. | 09 Jul 2026 | 10,354 | 20,895 | - | 100.2 | 1,037,678 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 101.97 per share. | 09 Jul 2026 | 5,566 | 0 | - | 102.0 | 567,565 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 8,224 | 71,776 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 09 Apr 2026 | 8,224 | 8,224 | - | 17.9 | 147,045 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 89.84 per share. | 09 Apr 2026 | 8,224 | 0 | - | 89.8 | 738,844 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 74,367 | 10,399 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 31 Mar 2026 | 74,367 | 74,367 | - | 8.4 | 627,657 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 83.90 per share. | 31 Mar 2026 | 59,800 | 26,701 | - | 83.9 | 5,017,220 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 31 Mar 2026 | 40,000 | 114,367 | - | 17.9 | 715,200 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 40,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 78.86 per share. | 31 Mar 2026 | 21,825 | 91,152 | - | 78.9 | 1,721,120 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 84.57 per share. | 31 Mar 2026 | 19,469 | 7,232 | - | 84.6 | 1,646,493 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 85.54 per share. | 31 Mar 2026 | 7,232 | 0 | - | 85.5 | 618,625 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 82.84 per share. | 31 Mar 2026 | 2,366 | 86,501 | - | 82.8 | 195,999 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 80.25 per share. | 31 Mar 2026 | 1,485 | 89,667 | - | 80.2 | 119,171 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 78.33 per share. | 31 Mar 2026 | 1,390 | 112,977 | - | 78.3 | 108,879 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 81.36 per share. | 31 Mar 2026 | 800 | 88,867 | - | 81.4 | 65,088 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Sale of securities on an exchange or to another person at price $ 45.18 per share. | 04 Dec 2025 | 20,000 | 0 | - | 45.2 | 903,600 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 04 Dec 2025 | 20,000 | 20,000 | - | 8.4 | 168,800 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 20,000 | 84,766 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 20,000 | 104,766 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 09 Sep 2025 | 20,000 | 0 | - | 35 | 700,000 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 09 Sep 2025 | 20,000 | 20,000 | - | 8.4 | 168,800 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) |